Thrombocytopenia following percutaneous coronary intervention

Journal of Interventional Cardiology

Volumn 24, Issue 1, 2011, Pages 15-26

  Shenoy, Chetan ^a   Harjai, Kishore J ^a  

^a GUTHRIE RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ARGATROBAN; CLOPIDOGREL; DANAPAROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPTIFIBATIDE; FONDAPARINUX; HEPARIN; HIRULOG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; THIENOPYRIDINE DERIVATIVE; THROMBOCYTE FACTOR 4; TICLOPIDINE; TIROFIBAN;

ACUTE CORONARY SYNDROME; AORTA BALLOON; ARTICLE; CARDIOVASCULAR RISK; CASE STUDY; COCHRANE LIBRARY; COHORT ANALYSIS; DATA BASE; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; EMBASE; HEALTH CARE QUALITY; HEART INFARCTION; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; LUNG EMBOLISM; MEDLINE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT CARE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PSEUDOTHROMBOCYTOPENIA; RISK FACTOR; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ANGIOPLASTY, BALLOON, CORONARY; ANTICOAGULANTS; HUMANS; INCIDENCE; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; PROGNOSIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; THROMBOCYTOPENIA; TIME FACTORS;

EID: 79951593545     PISSN: 08964327     EISSN: 15408183     Source Type: Journal    
DOI: 10.1111/j.1540-8183.2009.00515.x     Document Type: Article

References (88)

1. Lloyd-Jones D, Adams R, Carnethon M, et al,. Heart disease and stroke statistics-2009 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation, 2009; 119: e21-e181.
2. Wang TY, Ou FS, Roe MT, et al,. Incidence and prognostic significance of thrombocytopenia developed during acute coronary syndrome in contemporary clinical practice. Circulation 2009; 119: 2454-2462.
3. Merlini PA, Rossi M, Menozzi A, et al,. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing co (Pubitemid 38625397)
4. Nikolsky E, Sadeghi HM, Effron MB, et al,. Impact of in-hospital acquired thrombocytopenia in patients undergoing primary angioplasty for acute myocardial infarction. Am J Cardiol 2005; 96: 474-481. (Pubitemid 41132760)
5. Berkowitz SD, Sane DC, Sigmon KN, et al,. Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group. J Am Coll Cardiol 1998; 32: 311-319. (Pubitemid 28396477)
6. Shenoy C, Orshaw P, Devarakonda S, Harjai KJ,. Occurrence, predictors, and outcomes of post-percutaneous coronary intervention thrombocytopenia in an unselected population. J Interv Cardiol 2009; 22: 156-162.
7. Kereiakes DJ, Berkowitz SD, Lincoff AM, et al,. Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade. Am Heart J 2000; 140: 74-80. (Pubitemid 30471244)
8. Schafer AI,. Thrombocytosis. N Engl J Med 2004; 350: 1211-1219. (Pubitemid 38339365)
9. Warkentin TE, Roberts RS, Hirsh J, et al,. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med 2003; 163: 2518-2524. (Pubitemid 37385796)
10. Payne BA, Pierre RV,. Pseudothrombocytopenia: A laboratory artifact with potentially serious consequences. Mayo Clin Proc 1984; 59: 123-125. (Pubitemid 14193339)
11. Sane DC, Damaraju LV, Topol EJ, et al,. Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy. J Am Coll Cardiol 2000; 36: 75-83. (Pubitemid 30466115)
12. Bizzaro N,. EDTA-dependent pseudothrombocytopenia: A clinical and epidemiological study of 112 cases, with 10-year follow-up. Am J Hematol 1995; 50: 103-109.
13. Arepally GM, Ortel TL,. Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med 2006; 355: 809-817.
14. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al,. ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention-summary article: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006; 113: 156-175. (Pubitemid 43958502)
15. Oliveira GB, Crespo EM, Becker RC, et al,. Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. Arch Intern Med 2008; 168: 94-102.
16. Greer IA, Nelson-Piercy C,. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: A systematic review of safety and efficacy. Blood 2005; 106: 401-407. (Pubitemid 40981229)
17. Lindhoff-Last E, Nakov R, Misselwitz F, et al,. Incidence and clinical relevance of heparin-induced antibodies in patients with deep vein thrombosis treated with unfractionated or low-molecular-weight heparin. Br J Haematol 2002; 118: 1137-1142. (Pubitemid 35025982)
18. Martel N, Lee J, Wells PS,. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: A meta-analysis. Blood 2005; 106: 2710-2715. (Pubitemid 41510744)
19. Pohl C, Kredteck A, Bastians B, et al,. Heparin- induced thrombocytopenia in neurologic patients treated with low-molecular-weight heparin. Neurology 2005; 64: 1285-1287.
20. Warkentin TE, Greinacher A, Koster A, et al,. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 340S-380S. (Pubitemid 351892970)
21. Warkentin TE, Kelton JG,. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001; 344: 1286-1292. (Pubitemid 32372963)
22. Said SM, Hahn J, Schleyer E, et al,. Glycoprotein IIb/IIIa inhibitor-induced thrombocytopenia: Diagnosis and treatment. Clin Res Cardiol 2007; 96: 61-69. (Pubitemid 46233207)
23. Dasgupta H, Blankenship JC, Wood GC, et al,. Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: A pooled analysis. Am Heart J 2000; 140: 206-211. (Pubitemid 30641579)
24. Aster RH,. Immune thrombocytopenia caused by glycoprotein IIb/IIIa inhibitors. Chest 2005; 127: 53S-59S. (Pubitemid 40224082)
25. Shantsila E, Lip GY, Chong BH,. Heparin-induced thrombocytopenia: A contemporary clinical approach to diagnosis and management. Chest 2009; 135: 1651-1664.
26. Curtis BR, Divgi A, Garritty M, Aster RH,. Delayed thrombocytopenia after treatment with abciximab: A distinct clinical entity associated with the immune response to the drug. J Thromb Haemost 2004; 2: 985-992. (Pubitemid 40185747)
27. Trapolin G, Savonitto S, Merlini PA, et al,. Delayed profound thrombocytopenia after abciximab administration for coronary stenting in acute coronary syndrome. Case reports and review of the literature. Ital Heart J 2005; 6: 647-651.
28. Jenkins LA, Lau S, Crawford M, Keung YK,. Delayed profound thrombocytopenia after c7E3 Fab (abciximab) therapy. Circulation 1998; 97: 1214-1215. (Pubitemid 28152900)
29. Sharma S, Bhambi B, Nyitray W, et al,. Delayed profound thrombocytopenia presenting 7 days after use of abciximab (ReoPro). J Cardiovasc Pharmacol Ther 2002; 7: 21-24. (Pubitemid 34408820)
30. Kaluski E, Leitman M, Khiger I, et al,. Delayed thrombocytopenia following abciximab therapy. Int J Cardiovasc Intervent 2001; 4: 151-155. (Pubitemid 34297068)
31. Reddy MS, Carmody TJ, Kereiakes DJ,. Severe delayed thrombocytopenia associated with abciximab (ReoPro) therapy. Catheter Cardiovasc Interv 2001; 52: 486-488. (Pubitemid 32275041)
32. McCorry RB, Johnston P,. Fatal delayed thrombocytopenia following abciximab therapy. J Invasive Cardiol 2006; 18: E173-E174. (Pubitemid 44680987)
33. Nurden P, Clofent-Sanchez G, Jais C, et al,. Delayed immunologic thrombocytopenia induced by abciximab. Thromb Haemost 2004; 92: 820-828. (Pubitemid 39386710)
34. Onitilo AA,. Delayed profound thrombocytopenia associated with eptifibatide. Am J Hematol 2006; 81: 984. (Pubitemid 44864461)
35. Bosco A, Kidson-Gerber G, Dunkley S,. Delayed tirofiban-induced thrombocytopenia: Two case reports. J Thromb Haemost 2005; 3: 1109-1110. (Pubitemid 41632854)
36. Dunkley S, Evans S, Gaudry L, et al,. Two distinct subgroups of tirofiban-induced thrombocytopenia exist due to drug dependent antibodies that cause platelet activation and increased ischaemic events. Platelets 2005; 16: 462-468. (Pubitemid 43109919)
37. Tcheng JE, Kereiakes DJ, Lincoff AM, et al,. Abciximab readministration: Results of the ReoPro Readministration Registry. Circulation 2001; 104: 870-875. (Pubitemid 32778035)
38. Topol EJ, Moliterno DJ, Herrmann HC, et al,. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001; 344: 1888-1894. (Pubitemid 32553357)
39. Moshiri S, Di Mario C, Liistro F, et al,. Severe intracranial hemorrhage after emergency carotid stenting and abciximab administration for postoperative thrombosis. Catheter Cardiovasc Interv 2001; 53: 225-228. (Pubitemid 32532185)
40. Vahdat B, Canavy I, Fourcade L, et al,. Fatal cerebral hemorrhage and severe thrombocytopenia during abciximab treatment. Catheter Cardiovasc Interv 2000; 49: 177-180. (Pubitemid 30075543)
41. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N Engl J Med 1997; 336: 1689-1696.
42. Hongo RH, Brent BN,. Association of eptifibatide and acute profound thrombocytopenia. Am J Cardiol 2001; 88: 428-431. (Pubitemid 32823310)
43. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomised, placebo-controlled trial. Lancet 2000; 356: 2037-2044.
44. Yoder M, Edwards RF,. Reversible thrombocytopenia associated with eptifibatide. Ann Pharmacother 2002; 36: 628-630. (Pubitemid 34270277)
45. Coons JC, Barcelona RA, Freedy T, et al,. Eptifibatide-associated acute, profound thrombocytopenia. Ann Pharmacother 2005; 39: 368-372. (Pubitemid 40165232)
46. Paradiso-Hardy FL, Madan M, Radhakrishnan S, et al,. Severe thrombocytopenia possibly related to readministration of eptifibatide. Catheter Cardiovasc Interv 2001; 54: 63-67.
47. Rezkalla SH, Hayes JJ, Curtis BR, et al,. Eptifibatide-induced acute profound thrombocytopenia presenting as refractory hypotension. Catheter Cardiovasc Interv 2003; 58: 76-79. (Pubitemid 36055306)
48. Epelman S, Nair D, Downey R, et al,. Eptifibatide-induced thrombocytopenia and thrombosis. J Thromb Thrombolysis 2006; 22: 151-154. (Pubitemid 44473566)
49. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. N Engl J Med 1998; 338: 1498-1505.
50. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. Circulation 1997; 96: 1445-1453.
51. Steinhubl SR, Tan WA, Foody JM, et al,. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. JAMA 1999; 281: 806-810. (Pubitemid 29113740)
52. Zakarija A, Bandarenko N, Pandey DK, et al,. Clopidogrel-associated TTP: An update of pharmacovigilance efforts conducted by independent researchers, pharmaceutical suppliers, and the Food and Drug Administration. Stroke 2004; 35: 533-537. (Pubitemid 38174443)
53. Bennett CL, Connors JM, Carwile JM, et al,. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 2000; 342: 1773-1777. (Pubitemid 30390236)
54. Yeh SP, Hsueh EJ, Wu H, Wang YC,. Ticlopidine-associated aplastic anemia. A case report and review of literature. Ann Hematol 1998; 76: 87-90. (Pubitemid 28118730)
55. Oomen PH, Tulleken JE, Zijlstra JG,. Hemolytic uremic syndrome in a patient treated with clopidogrel. Ann Intern Med 2000; 132: 1006. (Pubitemid 30397606)
56. Balamuthusamy S, Arora R,. Hematologic adverse effects of clopidogrel. Am J Ther 2007; 14: 106-112. (Pubitemid 46278671)
57. Oo TH,. Clopidogrel-associated thrombotic thrombocytopenic purpura presenting with coronary artery thrombosis. Am J Hematol 2006; 81: 890-891. (Pubitemid 44682195)
58. von Mach MA, Eich A, Weilemann LS, et al,. Subacute coronary stent thrombosis in a patient developing clopidogrel associated thrombotic thrombocytopenic purpura. Heart 2005; 91: e14.
59. Vonderheide RH, Thadhani R, Kuter DJ,. Association of thrombocytopenia with the use of intra-aortic balloon pumps. Am J Med 1998; 105: 27-32. (Pubitemid 28346106)
60. Bream-Rouwenhorst HR, Hobbs RA, Horwitz PA,. Thrombocytopenia in patients treated with heparin, combination antiplatelet therapy, and intra-aortic balloon pump counterpulsation. J Interv Cardiol 2008; 21: 350-356. (Pubitemid 352033293)
61. Walls JT, Boley TM, Curtis JJ, et al,. Heparin induced thrombocytopenia in patients undergoing intra-aortic balloon pumping after open heart surgery. ASAIO J 1992; 38: M574-M576.
62. Burkhoff D, Cohen H, Brunckhorst C, et al,. A randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock. Am Heart J 2006; 152: 469-e1-469-e8.
63. Grosbois B, Milton D, Beneton C, et al,. Thrombocytopenia induced by angiotensin converting enzyme inhibitors. BMJ 1989; 298: 189-190. (Pubitemid 19039690)
64. Khan MA, Bashi SA, Noah MS,. Captopril associated isolated thrombocytopenia. Ir Med J 1987; 80: 101.
65. Walsh KP, Branagan J, Walsh MJ,. Reversible severe thrombocytopaenia associated with captopril therapy. Ir Med J 1986; 79: 43-44. (Pubitemid 17195103)
66. Groneberg DA, Barkhuizen A, Jeha T,. Simvastatin-induced thrombocytopenia. Am J Hematol 2001; 67: 277.
67. McCarthy LJ, Porcu P, Fausel CA, et al,. Thrombotic thrombocytopenic purpura and simvastatin. Lancet 1998; 352: 1284-1285. (Pubitemid 28470349)
68. Sundram F, Roberts P, Kennedy B, et al,. Thrombotic thrombocytopenic purpura associated with statin treatment. Postgrad Med J 2004; 80: 551-552. (Pubitemid 39265301)
69. Warkentin TE, Maurer BT, Aster RH,. Heparin-induced thrombocytopenia associated with fondaparinux. N Engl J Med 2007; 356: 2653-2655; discussion-5.
70. Rota E, Bazzan M, Fantino G,. Fondaparinux-related thrombocytopenia in a previous low-molecular-weight heparin (LMWH)-induced thrombocytopenia (HIT). Thromb Haemost 2008; 99: 779-781. (Pubitemid 351694236)
71. Warkentin TE, Lim W,. Can heparin-induced thrombocytopenia be associated with fondaparinux use? Reply to a rebuttal. Journal of Thrombosis and Haemostasis 2008; 6: 1243-1246. (Pubitemid 351859141)
72. Rabelink TJ, Zwaginga JJ, Koomans HA, Sixma JJ,. Thrombosis and hemostasis in renal disease. Kidney Int 1994; 46: 287-296. (Pubitemid 24253033)
73. Mattichak SJ, Dixon SR, Shannon F, et al,. Failed percutaneous coronary intervention: A decade of experience in 21,000 patients. Catheter Cardiovasc Interv 2008; 71: 131-137. (Pubitemid 351293751)
74. Huxtable LM, Tafreshi MJ, Rakkar AN,. Frequency and management of thrombocytopenia with the glycoprotein IIb/IIIa receptor antagonists. Am J Cardiol 2006; 97: 426-429. (Pubitemid 43133064)
75. Warkentin TE,. Heparin-induced thrombocytopenia: Diagnosis and management. Circulation 2004; 110: e454-e458.
76. Tcheng JE,. Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: Bleeding, reversal, thrombocytopenia, and retreatment. Am Heart J 2000; 139: S38-S45. (Pubitemid 30091780)
77. Ellis SG, Roubin GS, Wilentz J, et al,. Effect of 18- to 24-hour heparin administration for prevention of restenosis after uncomplicated coronary angioplasty. Am Heart J 1989; 117: 777-782. (Pubitemid 19097280)
78. Fail PS, Maniet AR, Banka VS,. Subcutaneous heparin in postangioplasty management: Comparative trial with intravenous heparin. Am Heart J 1993; 126: 1059-1067. (Pubitemid 23330404)
79. Friedman HZ, Cragg DR, Glazier SM, et al,. Randomized prospective evaluation of prolonged versus abbreviated intravenous heparin therapy after coronary angioplasty. J Am Coll Cardiol 1994; 24: 1214-1219. (Pubitemid 24331859)
80. Garachemani AR, Kaufmann U, Fleisch M, et al,. Prolonged heparin after uncomplicated coronary interventions: A prospective, randomized trial. Am Heart J 1998; 136: 352-356. (Pubitemid 28368861)
81. Harjai KJ, Stone GW, Grines CL, et al,. Usefulness of routine unfractionated heparin infusion following primary percutaneous coronary intervention for acute myocardial infarction in patients not receiving glycoprotein IIb/IIIa inhibitors. Am J Cardiol 2007; 99: 202-207. (Pubitemid 46072759)
82. Juergens CP, Crozier JA, Robinson JT, et al,. Unfractionated heparin use after percutaneous coronary intervention: Results of a trial with a vascular ultrasound endpoint. Heart Lung Circ 2008; 17: 107-113. (Pubitemid 351377556)
83. Rabah M, Mason D, Muller DW, et al,. Heparin after percutaneous intervention (HAPI): A prospective multicenter randomized trial of three heparin regimens after successful coronary intervention. J Am Coll Cardiol 1999; 34: 461-467.
84. Zibaeenezhad MJ, Mazloum Y,. Heparin infusion after successful percutaneous coronary intervention: A prospective, randomized trial. Acta Cardiol 2009; 64: 65-70.
85. Jiang CY, Zhao LL, Wang JA, et al,. Anticoagulation therapy in intra-aortic balloon counterpulsation: Does IABP really need anti-coagulation? J Zhejiang Univ Sci 2003; 4: 607-611.
86. Cooper HA, Thompson E, Panza JA,. The role of heparin anticoagulation during intra- aortic balloon counterpulsation in the coronary care unit. Acute Card Care 2008; 10: 214-220.
87. Levine RL, Hursting MJ, McCollum D,. Argatroban therapy in heparin-induced thrombocytopenia with hepatic dysfunction. Chest 2006; 129: 1167-1175.
88. Kiser TH, Fish DN,. Evaluation of bivalirudin treatment for heparin-induced thrombocytopenia in critically ill patients with hepatic and/or renal dysfunction. Pharmacotherapy 2006; 26: 452-460.